Insoluble Elastin Composition for Soft Tissue Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dermal fillers often induce adverse host responses such as inflammation, calcification, and fibrous encapsulation due to foreign body reactions, and existing materials like synthetic biomaterials and animal-derived extracellular matrix components have limitations including immune reactions and persistence issues.
Innovation Solution
A composition comprising isolated non-human or human elastin with a molecular weight greater than 100 kDa, substantially insoluble in water, and suspended in a pharmaceutically acceptable carrier, which is cross-linked or chemically altered to reduce immunogenicity and improve persistence, is used for soft tissue augmentation, avoiding calcification and long-term inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If synthetic biomaterials like silicone, polylactic acid, Teflon are used for dermal filling, then tissue bulking is achieved, but foreign body reactions occur including inflammation, fibrous encapsulation, calcification, and scarring
Solution Approach 1:
The invention changes the chemical composition parameters by using purified human elastin with specific molecular weight (>100 kDa) and cross-linking degree, transforming it from a soluble protein to an insoluble, stable form that mimics native extracellular matrix, thereby reducing immunogenicity while maintaining tissue bulk
Solution Approach 2:
The invention creates a composite material system combining elastin with specific carriers (collagen, hyaluronic acid, or water) to achieve both tissue bulk and biocompatibility, where the carrier provides structural support while elastin provides elasticity and longevity without triggering strong foreign body reactions
2Reliability
If animal-derived extracellular matrix materials like bovine collagen or hyaluronic acid are used, then natural tissue compatibility is improved, but immune reactions occur due to non-human origin and high viscosity makes injection difficult
Solution Approach 1:
The invention changes the species origin parameter from animal-derived to human-derived elastin, and modifies the physical state from soluble to insoluble through cross-linking, creating a material that is both naturally compatible and immunologically acceptable while maintaining injectability through controlled particle size and carrier selection
Solution Approach 2:
The invention copies the structure and function of native human elastin from blood vessels, purifying and cross-linking it to recreate the natural extracellular matrix environment, thereby achieving tissue compatibility without the immune reactions associated with animal-derived alternatives
3Duration of action of stationary object
If elastin preparations are used for dermal filling, then longevity and elasticity are improved, but calcification occurs upon implantation
Solution Approach 1:
The invention changes the molecular weight parameter to greater than 100 kDa and controls the cross-linking degree to achieve insolubility, creating an elastin preparation that is stable and persistent in tissue without triggering calcification, unlike smaller or improperly cross-linked elastin preparations
Solution Approach 2:
The invention uses specific carriers (water, collagen, or hyaluronic acid) to suspend the cross-linked elastin particles, creating an injectable formulation that maintains proper hydration and prevents the dry, calcified state that occurs with improperly formulated elastin preparations
Data Source
AI summary
The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.